LPL Financial
IOVA icon

LPL Financial’s Iovance Biotherapeutics IOVA Stock Holding History

LPL Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$69.8K Buy
+19,900
New +$63.6K ﹤0.01% 5735
2025
Q3 		– Sell
-70,000
Closed -$120K – 5895
2025
Q2 		$120K Buy
70,000
+50,000
+250% +$124K ﹤0.01% 5228
2025
Q1 		$66.6K Buy
+20,000
New +$103K ﹤0.01% 5114
2024
Q4 		– Sell
-10,000
Closed -$93.9K – 5371
2024
Q3 		$93.9K Buy
+10,000
New +$94.7K ﹤0.01% 4903

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

LPL Financial's IOVA Position: Q1 2026 in Review

LPL Financial reduced its Iovance Biotherapeutics (IOVA) stake by 8.6% in Q1 2026, selling an estimated $172K and leaving 569,234 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #3513.

LPL Financial first reported a position in IOVA in Q3 2019 and has held it in 23 quarters since. The position peaked at $3.57M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • LPL Financial held 569,234 shares of Iovance Biotherapeutics worth $2M as of Q1 2026.
  • LPL Financial sold 53,838 Iovance Biotherapeutics shares in Q1 2026, an estimated $172K.
  • Iovance Biotherapeutics made up ﹤0.01% of LPL Financial's portfolio in Q1 2026, its #3513 holding.
  • LPL Financial first reported a position in Iovance Biotherapeutics in Q3 2019 and has held it in 23 quarters since.
  • LPL Financial's Iovance Biotherapeutics position peaked at $3.57M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on LPL Financial's 13F filing for Q1 2026, filed 6 May 2026.